1Lopez-Sendon J, Swedberg K, McMurray J, et al. The Task Force on Beta-Blockers of the European Society of Cardiology. Expert consensus document on β-adrenergic receptor blockers. Eur Heart J,2004,25:1341-1362.
2Lopez-Sendon J, Swedberg K, McMurray J, et al. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J, 2004,25:1454-1470.
3Packer M, Poole-Wilson PA, Armstrong PW, et al. On behalf of the ATLAS study group. Comparative effects of low and high doses of the angiotension-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation,1999,100:2312-2318.
4The NETWORK investigators. Clinical outcome with enalapril in systematic chronic heart failure, a dose comparison. Eur Heart J,1998,19:481-489.
5Pitt B, Poole-Wilson PA, Segl R. On behalf of the ELITE II investigators Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial - the Losartan Heart Failure Survival Study ELITE II. Lancet,2000,355:1582-1587.
6Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee for the OPTIMAAL Study Group Effects of losartan and captopril on mortality and morbidity high -risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Lancet,2002,360:752-760.
7Pfeffer MA, McMurray JJ, Velasquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure. left ventricular dysfunction, or both. N Eng J Med,2003,349:1893-1906.
8Mcmurray JJV, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin converting-enzyme inhibitors: the CHARM-ADDED trial. Lancet,2003,362:761-771.
9Torp-Pedersen C, Kober L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet,1999,354:9-12.
10Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-PreservedTrial. Lancet,2003,326:777-781.
